Isomorphic Labs and MSD Partner on AI Oncology Drug Discovery

Unite.AI
Read full story· 4 min
Isomorphic Labs and MSD have launched a strategic collaboration to discover small-molecule oncology drugs by combining Isomorphic Labs' AI drug design engine with MSD's proprietary datasets and expertise. The partnership focuses on early-stage drug discovery targeting a strategically important oncology target, with Isomorphic Labs handling computational design and MSD managing subsequent development stages.

What happened

On November 19, 2026, Isomorphic Labs and MSD announced a strategic partnership to discover new small-molecule drugs for cancer. The collaboration will use Isomorphic Labs’ AI drug design engine, IsoDDE, alongside proprietary datasets and expertise from MSD. Isomorphic Labs is responsible for computational drug design, while MSD will handle preclinical and clinical development, manufacturing, and commercialization of any resulting drugs. The partnership is focused on early-stage research targeting a specific oncology area considered strategically important by both companies.

Key details

  • Announcement date: November 19, 2026
  • Isomorphic Labs will use its IsoDDE AI drug design engine
  • MSD provides proprietary datasets and discovery expertise
  • Isomorphic Labs receives an upfront payment, milestone payments, and tiered royalties
  • Isomorphic Labs can opt to co-fund development for higher royalties

Why it matters

Pharmaceutical companies and researchers working in oncology drug discovery may see faster or more efficient identification of new drug candidates as a result of this partnership. Isomorphic Labs gains new revenue streams and the option to participate more deeply in drug development. MSD gets access to advanced AI-driven design capabilities, potentially accelerating its pipeline for cancer treatments.


More in Healthcare